Crucially, for the first time, we highlight a novel synergistic association of dual metformin and GLP‐1 RA treatment with (reduced) cancer incidence in patients with T2D, both with and without obesity. This evidence concerns the gene GLP1R and obesity due to melanocortin 4 receptor deficiency.